Orion Corp
KRX:271560
Gross Margin
Orion Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
|
Orion Corp
KRX:271560
|
4.7T KRW |
39%
|
|
| JP |
G
|
Goyo Foods Industry Co Ltd
TSE:2230
|
53.2T JPY |
34%
|
|
| CH |
|
Nestle SA
SIX:NESN
|
232.4B CHF |
47%
|
|
| US |
|
Mondelez International Inc
NASDAQ:MDLZ
|
89B USD |
39%
|
|
| FR |
|
Danone SA
PAR:BN
|
45.6B EUR |
50%
|
|
| ZA |
T
|
Tiger Brands Ltd
JSE:TBS
|
42.7B Zac |
28%
|
|
| US |
|
Kraft Heinz Co
NASDAQ:KHC
|
35.9B USD |
35%
|
|
| US |
|
Hershey Co
NYSE:HSY
|
34.5B USD |
47%
|
|
| US |
|
General Mills Inc
NYSE:GIS
|
32.7B USD |
35%
|
|
| CN |
|
Foshan Haitian Flavouring and Food Co Ltd
SSE:603288
|
227.9B CNY |
35%
|
|
| CH |
|
Chocoladefabriken Lindt & Spruengli AG
SIX:LISN
|
26.6B CHF |
65%
|
Orion Corp
Glance View
Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Orion Corp's most recent financial statements, the company has Gross Margin of 38.5%.
You don't have any saved screeners yet